Harshabad Singh, Program Director Hepatobiliary and Pancreas Cancers at Mass general Brigham, shared on LinkedIn:
”We are entering a truly transformative era in pancreatic cancer care.
At Mass General Brigham, it is a privilege to now offer daraxonrasib and other novel KRAS inhibitors to our patients. But this is only the beginning!
The real opportunity lies in learning from every patient we treat and pairing those insights with cutting-edge translational science to extend and deepen these benefits.
Our multidisciplinary translational program Aparna Parikh, Leon Pappas, Harshabad Singh, Colin Weekes, Motaz Qadan, Thomas Clancy, Ryan Corcoran, Jennifer Wo, Dejan Juric, David Ting, William Hwang, Liron Bar-Peled, Andrew Liss is focused on advancing the next generation of pancreatic cancer therapeutics.”
Aparna Parikh, Program Director for the GI Medical Oncology Program at Mass General Brigham, shared Harshabad Singh‘s post, adding:
”In the short time we’ve had access to darox, we’ve treated over 50 patients through the EAP. This means many patients who never had the opportunity to receive treatment on trial are now able and now, many others like those with CRC are hoping for a broader RAS option for them.
Besides the EAP, we have a great portfolio of other RAS options available to patients! Exciting times!”
Other articles about pancreatic cancer on OncoDaily.